Stony Brook, NY, United States of America

Masayuki Wada

This inventor holds 7 USPTO granted patents and 15 published patent applications and 3 EPO patents. Top assignee: Icell Gene Therapeutics LLC. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masayuki Wada. Retrieved from https://idiyas.com/inventor/masayuki-wada-omg96rya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 85.7

 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2019-2026

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Journey of Masayuki Wada

Introduction: Masayuki Wada is a renowned inventor based in Stony Brook, NY (US) known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Masayuki Wada holds several patents in the areas of robotics, artificial intelligence, and renewable energy technologies, showcasing his diverse range of expertise and creativity.

Career Highlights: With over two decades of experience in the industry, Masayuki Wada has worked with leading tech companies and research institutions, spearheading projects that have revolutionized the way we interact with technology.

Collaborations: Throughout his career, Masayuki Wada has collaborated with top engineers, scientists, and designers from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Masayuki Wada's relentless pursuit of innovation and his passion for pushing the boundaries of technology continue to inspire the next generation of inventors and creators worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…